[Randomized, blind, parallel-controlled and multiple-centre clinical trial on the effectiveness and safety of leuprolide acetate in the treatment of endometriosis]

What Was Tested

This randomized controlled trial paper looks at Leuprolide in the context of endometriosis.

Who Took Part

The abstract describes 2012, patients taking part.

PubMed tags the participants as women only.

From Nov. 2007 to Oct. 2012, the patients who confirmed to be endometriosis were randomly divided into test group of 113 cases and control group of 116 cases.

After treatment, the ovarian mass volumes measured with type-B ultrasound, the scores of the patient's subjective symptoms during non-menstrual and menstruation days, the pelvic signs during non-menstrual days, the changes of hormones [estradiol (E2), FSH, LH], and adverse events were observed.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The patients were allocated by chance, so the Leuprolide group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Leuprolide.

The test drug was the sustained-release agent of leuprolide acetate.

The control drug was Enantone.

The drugs were used for 3 times in total.

What Was Measured

The subject headings attached to it are Antineoplastic Agents, Hormonal, Endometrial Neoplasms, Endometriosis, Estradiol, Hormones and Leuprolide.

What This Means in Plain Language

The paper is a randomized and double-blind study of Leuprolide in 2012, patients in people with endometriosis.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Zhonghua fu chan ke za zhi), a journal based in China.

More context: the Leuprolide compound page, Endometriosis research.